VivoSeq
Other

Budesonide

0

Pipeline Programs↗

4

Active Trials↗

10

Companies Involved↗

Budesonide is an early-stage landscape with 0 programs across 10 companies. The most active players are AstraZeneca, Orion Corporation, Orion Pharma, Novartis.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

87/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalOrion Corporation, Orion Pharma logo

Orion Corporation, Orion Pharma

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

PreclinicalL

Ligand Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

55

clinical trials

Completed41 · 75%
Terminated4 · 7%
Unknown status4 · 7%
Withdrawn2 · 4%
Active, not recruiting2 · 4%
Not yet recruiting1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

55 trials

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
Recruiting·AstraZeneca logoAstraZeneca·N/A·NCT06712563·2,000 enrolled
The Budesonide in Babies (BiB) Trial
Active, not recruiting·NNICHD Neonatal Research Network·Phase 3·NCT04545866·642 enrolled
Epigenetic Health Benefits of Budesonide
Active, not recruiting·UUniversity of British Columbia·Phase 4·NCT04342039·20 enrolled
Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia.
Not yet recruiting·HHospital Clinic of Barcelona·Phase 3·NCT04862377·50 enrolled
Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers
Completed·Orion Corporation, Orion Pharma logoOrion Corporation, Orion Pharma·Phase 1·NCT01668121·48 enrolled
Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte
Completed·Orion Corporation, Orion Pharma logoOrion Corporation, Orion Pharma·Phase 1·NCT01627158·72 enrolled
(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets
Completed·BBausch Health Americas, Inc.·Phase 3·NCT01100112·61 enrolled
Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT06139991·66 enrolled
Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol)
Completed·AstraZeneca logoAstraZeneca·N/A·NCT05862545·250 enrolled
Intratracheal Budesonide/Surfactant Prevents BPD
Completed·TTaipei Medical University·Phase 4·NCT03275415·310 enrolled
Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT05477108·108 enrolled
Study to Detect Oral Administration of Budesonide in Women.
Completed·PParc de Salut Mar·Phase 1·NCT03537326·4 enrolled
A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide)
Completed·UUniversity of British Columbia·Phase 2/3·NCT00175747·120 enrolled
A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 2·NCT00135408·115 enrolled
A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers
Completed·—·Phase 1·NCT02237508·90 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)